bintrafusp alfa

Bintrafusp alfa is a first-in-class bifunctional fusion protein designed to target two key immunosuppressive pathways in cancer. It consists of the extracellular domain of transforming growth factor beta receptor II (TGF-βRII), acting as a TGF-β "trap," fused to a human IgG1 monoclonal antibody that blocks programmed death ligand 1 (PD-L1). By simultaneously neutralizing TGF-β and inhibiting PD-L1, bintrafusp alfa aims to enhance anti-tumor immune responses by increasing natural killer cell and cytotoxic T lymphocyte activity, reversing epithelial-mesenchymal transition, and reducing tumor-induced immunosuppression. The drug has been investigated primarily for advanced solid tumors, including non-small cell lung cancer (NSCLC), biliary tract cancers, cervical cancer, anal cancer, and squamous cell carcinoma of the head and neck[1][3][5][8].

Other names

bintrafusp alfaM7824M-7824M 7824